These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11462019)

  • 41. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
    Van Rompay KK; Marthas ML; Lifson JD; Berardi CJ; Vasquez GM; Agatep E; Dehqanzada ZA; Cundy KC; Bischofberger N; Pedersen NC
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):761-73. PubMed ID: 9643376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronology of genetic changes in the vpu, env, and Nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques.
    McCormick-Davis C; Zhao LJ; Mukherjee S; Leung K; Sheffer D; Joag SV; Narayan O; Stephens EB
    Virology; 1998 Sep; 248(2):275-83. PubMed ID: 9721236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding.
    Rosenberg YJ; Jiang X; Cheever T; Coulter FJ; Pandey S; Sack M; Mao L; Urban L; Lees J; Fischer M; Smedley J; Sidener H; Stanton J; Haigwood NL
    J Virol; 2021 Aug; 95(18):e0026821. PubMed ID: 34190597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses.
    Abel K; Pahar B; Van Rompay KK; Fritts L; Sin C; Schmidt K; Colón R; McChesney M; Marthas ML
    J Virol; 2006 Jul; 80(13):6357-67. PubMed ID: 16775324
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge.
    Busch M; Abel K; Li J; Piatak M; Lifson JD; Miller CJ
    Vaccine; 2005 Jul; 23(31):4036-47. PubMed ID: 15963361
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.
    Ui M; Kuwata T; Igarashi T; Ibuki K; Miyazaki Y; Kozyrev IL; Enose Y; Shimada T; Uesaka H; Yamamoto H; Miura T; Hayami M
    Virology; 1999 Dec; 265(2):252-63. PubMed ID: 10600597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.
    Wang SW; Bertley FM; Kozlowski PA; Herrmann L; Manson K; Mazzara G; Piatak M; Johnson RP; Carville A; Mansfield K; Aldovini A
    AIDS Res Hum Retroviruses; 2004 Aug; 20(8):846-59. PubMed ID: 15320989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus.
    Rasmussen RA; Hofmann-Lehman R; Montefiori DC; Li PL; Liska V; Vlasak J; Baba TW; Schmitz JE; Kuroda MJ; Robinson HL; McClure HM; Lu S; Hu SL; Rizvi TA; Ruprecht RM
    J Med Primatol; 2002 Feb; 31(1):40-60. PubMed ID: 12076047
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Passive immunization of rhesus macaques against SIV infection and disease.
    Gardner M; Rosenthal A; Jennings M; Yee J; Antipa L; Robinson E
    AIDS Res Hum Retroviruses; 1995 Jul; 11(7):843-54. PubMed ID: 7546912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque.
    McKenna PM; Aye PP; Dietzschold B; Montefiori DC; Martin LN; Marx PA; Pomerantz RJ; Lackner A; Schnell MJ
    J Virol; 2004 Dec; 78(24):13455-9. PubMed ID: 15564456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sustained conservation of CD4+ T cells in multiprotein triple modality-immunized rhesus macaques after intrarectal challenge with simian immunodeficiency virus.
    Stolte-Leeb N; Sauermann U; Norley S; Fagrouch Z; Heeney J; Franz M; Hunsmann G; Stahl-Hennig C
    Viral Immunol; 2006; 19(3):448-57. PubMed ID: 16987063
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.
    Moog C; Dereuddre-Bosquet N; Teillaud JL; Biedma ME; Holl V; Van Ham G; Heyndrickx L; Van Dorsselaer A; Katinger D; Vcelar B; Zolla-Pazner S; Mangeot I; Kelly C; Shattock RJ; Le Grand R
    Mucosal Immunol; 2014 Jan; 7(1):46-56. PubMed ID: 23591718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-HIV IgM protects against mucosal SHIV transmission.
    Gong S; Tomusange K; Kulkarni V; Adeniji OS; Lakhashe SK; Hariraju D; Strickland A; Plake E; Frost PA; Ratcliffe SJ; Wang L; Lafer EM; Ruprecht RM
    AIDS; 2018 Jul; 32(11):F5-F13. PubMed ID: 29762161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge.
    Klein K; Veazey RS; Warrier R; Hraber P; Doyle-Meyers LA; Buffa V; Liao HX; Haynes BF; Shaw GM; Shattock RJ
    J Virol; 2013 Nov; 87(21):11604-16. PubMed ID: 23966410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.
    Wolbank S; Kunert R; Stiegler G; Katinger H
    J Virol; 2003 Apr; 77(7):4095-103. PubMed ID: 12634368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques.
    Hessell AJ; Jaworski JP; Epson E; Matsuda K; Pandey S; Kahl C; Reed J; Sutton WF; Hammond KB; Cheever TA; Barnette PT; Legasse AW; Planer S; Stanton JJ; Pegu A; Chen X; Wang K; Siess D; Burke D; Park BS; Axthelm MK; Lewis A; Hirsch VM; Graham BS; Mascola JR; Sacha JB; Haigwood NL
    Nat Med; 2016 Apr; 22(4):362-8. PubMed ID: 26998834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Older rhesus macaque infants are more susceptible to oral infection with simian-human immunodeficiency virus 89.6P than neonates.
    Chenine AL; Ferrantelli F; Hofmann-Lehmann R; Vangel MG; McClure HM; Ruprecht RM
    J Virol; 2005 Jan; 79(2):1333-6. PubMed ID: 15613361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.
    Ng CT; Jaworski JP; Jayaraman P; Sutton WF; Delio P; Kuller L; Anderson D; Landucci G; Richardson BA; Burton DR; Forthal DN; Haigwood NL
    Nat Med; 2010 Oct; 16(10):1117-9. PubMed ID: 20890292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.